Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Ozempic and similar medications are found not only to lose weight, but also finds more research. The new information is the most end of the fact that GLP-1 medicines are also reduced by people’s alcohol consumption.
Ireland and Saudi Arabia’s scientists have conducted a study involved in 200 patients who set GLP-1 medicine to manage their fat. They tend to reduce not only the drugs that people do not lose weight, but the most drinkers of the alcohol intake. The findings reinforce their work as an addictive treatment for GLP-1S and say researchers.
Semaglutide (active ingredient in Ozempic and Wegovy) and similar GLP-1 medications more effective In helping people lose more weight from a diet and single exercise. However, some scientists also began to help people reduce the bends of people, including harmful drugs such as food, opioids, cocaine, cocaine and alcoholic alcohol. Timely work make rich This anecdotal began to support observations.
This new job was promising because researchers have changed how people have changed alcohol use after the start of the GLP-1 therapy (many past similar studies were retrospective, which only looks back in time). Research participants were patients in real-life, either to lose weight or liraglutide or liraglutide (an old GLP-1 medication). Before the participants began to start drugs, the use of alcohol, then three and six months later asked to return to follow.
In total, 188 people returned to at least one follow-up visit. People who drink alcohol were reported to drink less than the beginning of a GLP-1 medication. This decrease will start the most drinkers (such as drinkers in a week), 68% of drinkers from an average of 8 drinks per week. This reduction level can be compared to the effectiveness of existing treatment for the effectiveness of alcohol use.
“Significantly reduced alcohol hackoul between our results, GLP-1 RAS and patients treated,” They wrote in documents written in their paper Submitted This weekend is about obesity in the annual European Congress. The findings were also published In the early year, in diabetes, obesity and metabolism in the magazine.
There are restrictions as a lack of research, management group and relatively small sample size. In the brain, GLP-1 receptors in the brain, GLP-1 receptors as alcoholic and potential addictive incentives are still suspicious, there are still some secrets. However, evidence is an assembly for GLP-1s, which is another life as a treatment for the disorders of the substance.
The authors note that there is a weak positive connection between how many alcohol and alcoholic alcoholics of alcohol, alcoholic alcohol are how rich in alcohol. Thus, at least these drugs can serve binary function for people who are fighting their weight and drinking habits.
“These results offer a potential therapeutic role for the use of GLP-1 RAS’s obesity and alcohol use, alcohol use and alcohol use,” said researchers.
As a result, the semaglutidin will conduct random and controlled clinical trials to know that some of the semaglutidin, the item of semaglutid is becoming a reliable front selection for disorders already continues.
